Australia - engelsk - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - moxonidine, quantity: 400 microgram - tablet, film coated - excipient ingredients: crospovidone; lactose monohydrate; ethylcellulose; titanium dioxide; povidone; macrogol 6000; hypromellose; purified talc; magnesium stearate; iron oxide red - for the treatment of hypertension.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - moxonidine, quantity: 200 microgram - tablet, film coated - excipient ingredients: magnesium stearate; macrogol 6000; povidone; ethylcellulose; crospovidone; purified talc; iron oxide red; titanium dioxide; hypromellose; lactose monohydrate - for the treatment of hypertension.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - efavirenz 600mg;  ; emtricitabine 200mg;  ; tenofovir disoproxil maleate 300mg equivalent to 245 mg tenofovir disoproxil - film coated tablet - active: efavirenz 600mg   emtricitabine 200mg   tenofovir disoproxil maleate 300mg equivalent to 245 mg tenofovir disoproxil excipient: colloidal silicon dioxide croscarmellose sodium hyprolose low-substituted hydroxypropylcellulose, lh 11 iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink 85f540043 sodium metabisulfite - indicated for the treatment of hiv infected adults over the age of 18 years, alone or in combination with other antiretroviral agents.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - ambrisentan 10mg - film coated tablet - 10 mg - active: ambrisentan 10mg excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry pink 85f540046 purified water - indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary arterial hypertension associated with connective tissue disease (pah-ctd), in patients with who functional class ii, iii or iv symptoms.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - ambrisentan 5mg - film coated tablet - 5 mg - active: ambrisentan 5mg excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry pink 85f540046 purified water - indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary arterial hypertension associated with connective tissue disease (pah-ctd), in patients with who functional class ii, iii or iv symptoms.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - folic acid 5mg - tablet - 5 mg - active: folic acid 5mg excipient: crospovidone lactose magnesium stearate maize starch povidone - the treatment of megaloblastic anaemia when folate deficiency is identified as the exclusive cause. folate deficiency is a consequence of inadequate dietary intake, malabsorption, or increased utilisation in conditions such as pregnancy, lactation, haemolyticanaemia, hyperthyroidism, exfoliative dermatitis, and chronic infection. prophylaxis of folate deficiency resulting from renal dialysis, pregnancy and lactation when the mother is malnourished, and chronic haemolytic states such as thalassaemia major or sickle-cell anaemia. label claim: treatment of megaloblastic anaemia due to folate deficiency. prevention of folate deficiency.

Irland - engelsk - HPRA (Health Products Regulatory Authority)

viatris limited - atorvastatin calcium trihydrate - film-coated tablet - hmg coa reductase inhibitors; atorvastatin

Irland - engelsk - HPRA (Health Products Regulatory Authority)

viatris limited - atorvastatin calcium trihydrate - film-coated tablet - hmg coa reductase inhibitors; atorvastatin

Irland - engelsk - HPRA (Health Products Regulatory Authority)

viatris limited - atorvastatin calcium trihydrate - film-coated tablet - hmg coa reductase inhibitors; atorvastatin

Irland - engelsk - HPRA (Health Products Regulatory Authority)

viatris limited - atorvastatin calcium trihydrate - film-coated tablet - hmg coa reductase inhibitors; atorvastatin